Although analysis of a small number of patients with PD-L1 TPS < 50% showed a correlation of the CX3CR1 score and response to anti-PD-L1 therapy, many patients with NSCLC and PD-L1 TPS < 50% undergo chemo-immunotherapy. This evidence concerns the gene CX3CR1 and non-small cell lung carcinoma.